Masimo Competitors

Masimo (NASDAQ:MASI) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Masimo and Abbott Laboratories, as reported by MarketBeat.

Masimo presently has a consensus target price of $261.1667, suggesting a potential upside of 3.59%. Abbott Laboratories has a consensus target price of $115.6875, suggesting a potential upside of 0.99%. Given Masimo's higher possible upside, equities research analysts clearly believe Masimo is more favorable than Abbott Laboratories.

Valuation and Earnings

This table compares Masimo and Abbott Laboratories' top-line revenue, earnings per share (EPS) and valuation.

Abbott Laboratories has higher revenue and earnings than Masimo. Abbott Laboratories is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Masimo and Abbott Laboratories' net margins, return on equity and return on assets.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Institutional & Insider Ownership

81.6% of Masimo shares are held by institutional investors. Comparatively, 72.6% of Abbott Laboratories shares are held by institutional investors. 11.5% of Masimo shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Masimo beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Institutional & Insider Ownership

81.6% of Masimo shares are held by institutional investors. Comparatively, 79.2% of Medtronic shares are held by institutional investors. 11.5% of Masimo shares are held by company insiders. Comparatively, 0.5% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Masimo and Medtronic, as reported by MarketBeat.

Masimo presently has a consensus target price of $261.1667, suggesting a potential upside of 3.59%. Medtronic has a consensus target price of $122.2963, suggesting a potential upside of 4.31%. Given Medtronic's stronger consensus rating and higher possible upside, analysts clearly believe Medtronic is more favorable than Masimo.

Valuation and Earnings

This table compares Masimo and Medtronic's top-line revenue, earnings per share (EPS) and valuation.

Medtronic has higher revenue and earnings than Masimo. Medtronic is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Masimo and Medtronic's net margins, return on equity and return on assets.

Summary

Masimo beats Medtronic on 8 of the 15 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 71.5% of Stryker shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 6.8% of Stryker shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Stryker, as reported by MarketBeat.com.

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Stryker has a consensus price target of $227.4783, suggesting a potential downside of 5.03%. Given Masimo's stronger consensus rating and higher probable upside, analysts plainly believe Masimo is more favorable than Stryker.

Earnings & Valuation

This table compares Masimo and Stryker's top-line revenue, earnings per share and valuation.

Stryker has higher revenue and earnings than Masimo. Stryker is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500.

Profitability

This table compares Masimo and Stryker's net margins, return on equity and return on assets.

Summary

Masimo beats Stryker on 8 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 86.5% of Intuitive Surgical shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Intuitive Surgical, as reported by MarketBeat.com.

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Intuitive Surgical has a consensus price target of $736.0588, suggesting a potential downside of 3.53%. Given Masimo's stronger consensus rating and higher probable upside, analysts plainly believe Masimo is more favorable than Intuitive Surgical.

Earnings & Valuation

This table compares Masimo and Intuitive Surgical's top-line revenue, earnings per share and valuation.

Intuitive Surgical has higher revenue and earnings than Masimo. Intuitive Surgical is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500.

Profitability

This table compares Masimo and Intuitive Surgical's net margins, return on equity and return on assets.

Summary

Intuitive Surgical beats Masimo on 9 of the 14 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 83.2% of Becton, Dickinson and shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 0.8% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Becton, Dickinson and, as reported by MarketBeat.com.

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Becton, Dickinson and has a consensus price target of $279.6667, suggesting a potential upside of 9.11%. Given Becton, Dickinson and's higher probable upside, analysts plainly believe Becton, Dickinson and is more favorable than Masimo.

Earnings & Valuation

This table compares Masimo and Becton, Dickinson and's top-line revenue, earnings per share and valuation.

Becton, Dickinson and has higher revenue and earnings than Masimo. Becton, Dickinson and is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Profitability

This table compares Masimo and Becton, Dickinson and's net margins, return on equity and return on assets.

Masimo (NASDAQ:MASI) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Institutional and Insider Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 80.9% of Edwards Lifesciences shares are owned by institutional investors. 11.5% of Masimo shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Masimo and Edwards Lifesciences, as reported by MarketBeat.com.

Masimo presently has a consensus price target of $261.1667, suggesting a potential upside of 3.59%. Edwards Lifesciences has a consensus price target of $90.8704, suggesting a potential upside of 5.60%. Given Edwards Lifesciences' higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Masimo.

Earnings & Valuation

This table compares Masimo and Edwards Lifesciences' top-line revenue, earnings per share and valuation.

Edwards Lifesciences has higher revenue and earnings than Masimo. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Masimo and Edwards Lifesciences' net margins, return on equity and return on assets.

Summary

Edwards Lifesciences beats Masimo on 8 of the 14 factors compared between the two stocks.